References
- Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
- Jaffee WB, Trucco E, Levy S, Weiss RD. Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat. 2007;33:33–42.
- Lee D, Bazydlo LAL, Reisfield GM, Goldberger BA. Urine spiking in a pain medicine clinic: an attempt to simulate adherence. Pain Med. 2014;1449–51. doi: 10.1111/pme.12663
- Person NB, Ehrenkranz JR. Fake urine samples for drug analysis: hot, but not hot enough. JAMA. 1988;259:841.
- Hull MJ, Bierer MF, Griggs DA, Long WH, Nixon AL, Flood JG. Urinary buprenorphine concentrations in patients treated with Suboxone®; as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay. J Anal Toxicol. 2008;32:516–521.
- Tzatzarakis MN, Vakonaki E, Kovatsi L et al. Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy. J Anal Toxicol. 2015;39:313–320.
- Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4:28–41.
- Havnes IA, Clausen T, Middelthon AL. ‘Diversion’ of methadone or buprenorphine: ‘harm’ versus ‘helping’. Harm Reduct J. 2013;10:24.
- Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication. J Addict Dis. 2014;1–17. doi: 10.1080/10550887.2014.975617
- Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy. 2008;19:450–458.
- Winstock AR, Lea T. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Subst. Use Misuse. 2010;45:240–252.
- Larance B, Lintzeris N, Ali R et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21–27.
- Lofwall MR, Wunsch MJ, Nuzzo PA, Walsh SL. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat. 2011;41:321–329.
- Wright N, D'Agnone O, Krajci P et al. Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. J. Public Health. 2015;e368–e374. doi: 10.1093/pubmed/fdv150
- Belivanis S, Tzatzarakis MN, Vakonaki E et al. Buprenorphine and nor-buprenorphine levels in head hair samples from former heroin users under Suboxone® treatment. Drug Test Anal. 2014;6(Suppl 1):93–100.
- Vindenes V, Yttredal B, Oiestad EL et al. Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with methadone or buprenorphine. J Anal Toxicol. 2011;35:32–39.